Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Lucid Diagnostics and Bluejay Diagnostics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
| Bluejay Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
Lucid Diagnostics presently has a consensus target price of $4.19, suggesting a potential upside of 342.89%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than Bluejay Diagnostics.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucid Diagnostics | $4.71 million | 40.76 | -$58.01 million | ($0.47) | -2.01 |
| Bluejay Diagnostics | N/A | N/A | -$6.85 million | ($11.63) | -0.10 |
Bluejay Diagnostics has lower revenue, but higher earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Lucid Diagnostics has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.
Institutional & Insider Ownership
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Lucid Diagnostics and Bluejay Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucid Diagnostics | -876.72% | N/A | -116.26% |
| Bluejay Diagnostics | N/A | -144.27% | -115.00% |
Summary
Lucid Diagnostics beats Bluejay Diagnostics on 9 of the 13 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
